| | | | |
|---|---|---|---|
| | **Name of the Issue: Niva Bupa Health Insurance Company Limited** | | |
| 1 | **Type of Issue** | Initial Public Offer | |
| 2 | **Issue Size (Rs. Mn)** | 22,000.00* | |
| | **Source: Prospectus dated November 12, 2024* | | |
| 3 | **Grade of issue along with name of the rating agency** | | |
| | **Name** | NA | |
| | **Grade** | NA | |
| 4 | **Subscription Level (Number of times)** | 1.90* | |
| | ** excluding Anchor Investor Portion and after technical rejections* | | |
| | *Source: Minutes for basis of allotment dated November 12, 2024* | | |

**5 QIB Holding (as a %age of Outstanding Capital) as disclosed to the stock exchanges**

| Particulars | % |
|---|---|
| (i) On Allotment ** | 18.20 |
| (ii) at the end of the 1st Quarter immediately after the listing of the issue (December 31, 2024) | 18.68 |
| (iii) at the end of 1st FY (March 31, 2025) | 18.60 |
| (iv) at the end of 2nd FY (March 31, 2026) | 27.09 |
| (v) at the end of 3rd FY (March 31, 2027) * | Not Available |

***Source: Institutions (domestic + foreign) holding as disclosed in the stock exchange filing*

** QIB Holding not disclosed as reporting for relevant period has not been completed.*

**6 Financials of the issuer**

| Parameters | 1st FY (March 31,2025) | 2nd FY (March 31,2026) | 3rd FY (March 31,2027)* |
|---|---|---|---|
| Total Income | 53,242.60 | 64,723 | Not Available |
| Net Profit/(Loss) for the period | 2,135.20 | 1,308 | Not Available |
| Paid-up equity share capital | 18,720.30 | 18,475 | Not Available |
| Reserves excluding revaluation reserves | 40,262.20 | 13,715 | Not Available |

** Financials not available as reporting for the relevant years has not been completed.*

**7 Trading Status**

The equity shares of Mankind Pharma Limited are listed on both the BSE Limited ("BSE") and the National Stock Exchange of India Limited ("NSE") (and together with BSE the "Stock Exchanges")

The equity shares have not been suspended or delisted.

| Particulars | Status |
|---|---|
| (i) at the end of 1st FY (March 31, 2025) | Frequently |
| (ii) at the end of 2nd FY (March 31, 2026) | Frequently |
| (iii) at the end of 3rd FY (March 31, 2027)* | Not Available |

** Trading status not disclosed as the relevant fiscal years have not been completed.*

**8 Change in Directors of Issuer from the disclosures in the offer document**

| Particulars | Name of Director | Appointed / Resigned |
|---|---|---|
| (i) at the end of 1st FY (March 31, 2025) | Pradeep Pant | Cessation |
| | Divya Sehgal | Resignation |
| | Mohit Gupta | Appointent |
| (ii) at the end of 2nd FY (March 31, 2026) | Vivek Anant Karve | Appointment |
| | Chandrashekhar Bhaskar Bhave | Resigend |
| | Roger William John Davis | Appointment |
| | Sridhar Srinivasan | Appointment |
| | Ankur Kharbanda | Appointment |
| | Vishwanath Mahendra | Appointment |
| | Partha Banerjee | Resigned |
| | Maninder Singh Juneja | Resigned |
| | Sridhar Srinivasan | Resigned |
| (iii) at the end of 3rd FY (March 31, 2027)* | Milind Gajanan Barve | Resignation |
| | Mr. Ashwani Bhatia | Appointed |
| | Mr. Christopher Patrick Carroll | Appointed |
| | Ms. Siobhan Djihan Moynihan | Appointed |

** Changes in Directors of Issuer not updated as the relevant financial years have not been completed*

**9 Status of implementation of project/ commencement of commercial production**

| | |
|---|---|
| (i) as disclosed in the offer document | Not applicable |
| (ii) Actual implementation | Not applicable |
| (iii) Reasons for delay in implementation, if any | Not applicable |

**10 Status of utilization of issue proceeds**

(i) as disclosed in the offer document

| Particulars | Amount proposed to be financed from Net Proceeds |
|---|---|
| To meet future capital requirements towards onward lending | 8000.00 |
| **Total Proceeds** | **8000.00** |

(ii) Actual implementation

| Particulars | Amount proposed to be financed from Net Proceeds | Actual Utilisation of Net Proceeds | Unutilised Net Proceeds |
|---|---|---|---|
| To meet future capital requirements towards onward lending | 8000.00 | 8000.00 | 0.00 |
| **Total Proceeds** | **8000.00** | **8000.00** | **0.00** |

*Source: Quarterly Results*

| | |
|---|---|
| (iii) Reasons for delay in implementation, if any | Not applicable |

**11 Comments of monitoring agency, if applicable**

| | |
|---|---|
| (i) Comments on use of funds | Not Applicable |
| (ii) Comments on deviations, if any, in the use of proceeds of the Issue from the objects stated in the Offer document | Not Applicable |
| (iii) Any other reservations expressed by the monitoring agency about the end use of funds | Not Applicable |

**12 Pricing Data**

| | |
|---|---|
| Designated Stock Exchange | NSE |
| Issue Price (Rs.) | 74.00 |
| Listing Date | 14-Nov-24 |

| Price parameters | At close of listing day | Close of 30th calendar day from listing day | Close of 90th calendar day from listing day | As at the end of the 1nd FY after the listing of the issue (31st March,2025) | | |
|---|---|---|---|---|---|---|
| | | | | Closing price | High | Low |
| Market Price | 74.00 | 83.60 | 79.3 | 75.92 | 77.79 | 75.62 |
| Nifty 50* | 23,523.70 | 24,768.30 | 23,045.25 | 23,165.70 | 23,565.15 | 23,136.40 |

| Price parameters | As at the end of the 2nd FY after the listing of the issue (31st March,2026) | | | As at the end of the 3rd FY after the listing of the issue (31st March,2027)[1] | | |
|---|---|---|---|---|---|---|
| | Closing price | High | Low | Closing price | High | Low |
| Market Price | 70.2 | 95.2 | 67.5 | Not Available | Not Available | Not Available |
| Nifty 50* | 22,331.4 | 26,328.6 | 22,161.6 | Not Available | Not Available | Not Available |

** Being index of NSE, the designated stock exchange*

*(1) The pricing data is not disclosed as the relevant fiscal years have not been completed*

**13 Basis for Issue Price**

| Accounting ratio | | Face Value per share (Rs.) | As disclosed in offer document* | At the end of 1st FY (March 31,2025) | At the end of 1st FY (March 31,2026) | At the end of 1st FY (March 31,2027)** |
|---|---|---|---|---|---|---|
| EPS (Diluted) | ***Company*** | | | | | |
| | *Consolidated* | | 0.51 | 1.20 | 0.71 | Not Available |
| | ***Peer Group:*** | | | | | |
| | Star Health and Allied Insurance Company | | 14.48 | 10.99 | 9.47 | |
| | ICICI Lombard General Insurance Company Ltd | | 39.03 | 50.25 | 55.24 | Not Available |
| | The New India Assurance Company Ltd | | 6.77 | 6.29 | 6.29 | Not Available |
| | ***Industry Avg*** | | **20.09** | 22.51 | 23.67 | Not Available |
| P/E | ***Company*** | | | | | |
| | *Consolidated* | | 148.00 | 63.27 | 98.89 | Not Available |
| | ***Peer Group:*** | | | | | |
| | Star Health and Allied Insurance Company | | 38.27 | 31.38 | 48.31 | Not Available |
| | ICICI Lombard General Insurance Company Ltd | | 48.91 | 35.66 | 30.69 | Not Available |
| | The New India Assurance Company Ltd | | 28.62 | 25.12 | 13.75 | Not Available |
| | ***Industry Avg*** | | **38.60** | 30.72 | 30.92 | Not Available |
| RoNW | ***Company*** | | | | | |
| | *Consolidated* | | 5.68% | 3.62% | 9.38% | Not Available |
| | ***Peer Group:*** | | | | | |
| | Star Health and Allied Insurance Company | | 14.35% | 9.20% | 7.38% | Not Available |
| | ICICI Lombard General Insurance Company Ltd | | 17.17% | 16.74% | 17.25% | Not Available |
| | The New India Assurance Company Ltd | | 5.13% | 4.42% | 3.51% | Not Available |
| | ***Industry Avg*** | | **12.22%** | 10.12% | 9.38% | Not Available |
| NAV per share | ***Company*** | | | | | |
| | *Consolidated* | | 12.06 | 32.28 | 20.57 | Not Available |
| | ***Peer Group:*** | | | | | |
| | Star Health and Allied Insurance Company | | 108.35 | 119.47 | 128.39 | Not Available |
| | ICICI Lombard General Insurance Company Ltd | | 242.75 | 302.27 | 323.19 | Not Available |
| | The New India Assurance Company Ltd | | 132.55 | 136.02 | 233.88 | Not Available |
| | ***Industry Avg*** | | **161.22** | 185.92 | 228.49 | Not Available |

*Notes*

** Sourced from Prospectus dated November 12, 2024.*

***Not available as the relevant fiscal years have not been completed / information not disclosed*

**14 Any other material information**

| Particulars | Date | Remarks |
|---|---|---|
| Raising of funds by way of issuance of Non-convertible debentures. | 30-07-2026 | |
| Completion of redemption of Debentures at par, pursuant to exercise of call option and payment of interest thereon. | 13-11-2026 | |

Source: Stock Exchange websites i.e. www.bseindia.com and www.nseindia.com